NSQ Drug Alert: CDSCO identifies 196 drugs that fail to perform quality tests in April 2025
The safety and efficacy of the drug are crucial and CDSCO (Central Drug Standards Control Organization) plays a crucial role in ensuring this through routine monitoring.
As part of routine regulatory oversight, CDSCO publishes monthly lists of unstandard quality (NSQ) and fake drugs on its portal. In April 2025, the Central Drug Laboratory identified 60 drug samples as NSQ, while the state drug testing laboratory identified 136 drugs, totaling 196 drug samples, which failed to meet quality standards.
The drug sample is identified as NSQ based on the failure of a drug sample with one or specified quality parameters.
Failure of batch products specific to government laboratory tests and no guarantee of any concerns about other drugs available on the market.
In April 2025, Bihar discovered a serious problem and found that a drug was false.
This means that the drug was manufactured unauthorized and was mistakenly using another company's brand name. The matter is currently under investigation and appropriate action is taken in accordance with the bill and rules.
Regular efforts in collaboration with state regulators are the identification of unqualified and false drugs.
The purpose is to detect and remove these unsafe drugs from the market, protect public health and ensure consumers can only use quality drugs.
This development highlights the urgent need to strengthen regulatory oversight and public awareness to ensure the safety and efficacy of drugs available to the public.
